{"id":15607,"date":"2012-10-17T11:30:00","date_gmt":"2012-10-17T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/big-pharma-scadono-i-brevetti-e-la-ricerca-di-nuovi-farmaci-e-a-rischio\/"},"modified":"2012-10-17T11:30:00","modified_gmt":"2012-10-17T09:30:00","slug":"big-pharma-scadono-i-brevetti-e-la-ricerca-di-nuovi-farmaci-e-a-rischio","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/big-pharma-scadono-i-brevetti-e-la-ricerca-di-nuovi-farmaci-e-a-rischio\/","title":{"rendered":"Big Pharma, patents expire and the search for new drugs is at risk"},"content":{"rendered":"

The pharmaceutical industry is facing the largest "expiration date" in its history: the end of his patents<\/b>. A $30 billion market this year alone, previously in the hands of large multinationals (Pfizer, Bristol-Myers, Merck, Eli Lilly, Novo Nordisk<\/b>), will pass to the smallest industries in the sector, in view of the end of the production rights of some of the best-known pills. Which will become generic drugs. The fall of the anti-cholesterol patent lipitor <\/b>(in March), for example, it cost Pfizer $9.6 billion<\/b>. In the United States alone, more than 6 million units were sold in 2011, before collapsing to 1 million 300 thousand in the last quarter.<\/p>\n

<\/span><\/p>\n

Something similar happens to the giant Bristol-Myers Squibb<\/b>: the patent on the Plavix<\/b>, the bestselling blood-clotting drug, expired this year and will cause the company to sue $4 billion in losses<\/b>. The most striking case is that of aids: theAtripla<\/b> it is the best-known drug for HIV-positive people and its patents will expire in the next 5 years. One of the active ingredients, theefavirenz<\/b>, will end in 2013, giving serious headaches to the top management GlaxoSmithKline.<\/b><\/p>\n

<\/span><\/p>\n

Pharmaceutical companies, which see revenues cut by 10-20 percent, are threatening a slowdown in the arrival of new products<\/b>. Perspective that worries the European Union, which last year granted Pfizer a six-month extension on the Lipitor patent. A sort of controversial subsidy for companies with staggering turnover.<\/p>\n

<\/span><\/p>\n

As much as the shareholders are not happy, patients benefit from it<\/b>: for Lipitor consumers the price of the drug collapsed in 24 hours. A similar example applies to Atripla, where the switch to the generic will save US health insurance funds almost 1 billion dollars.
(Riccardo Guidi @riccardoguidi87<\/i><\/span>)<\/span><\/i><\/p>\n

<\/span><\/p>\n

Read Panorama online<\/font><\/span><\/i><\/a> <\/p>\n

<\/span><\/p>\n

17-10-2012  <\/span><\/span>PANORAMA<\/span>L’industria farmaceutica sta affrontando la più grande «data di scadenza» della sua storia: la fine dei suoi brevetti. Solo quest’anno un mercato di 30 miliardi di dollari, prima nelle mani di gramdi multinazionali (Pfizer, Bristol-Myers, Merck, Eli Lilly, Novo Nordisk), passerà alle più piccole industrie del settore, in vista della fine dei diritti di produzione …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15607","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15607"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15607\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}